Metabolomic analysis to identify novel biomarkers of IBD activity
Research type
Research Study
Full title
Metabolomic analysis to identify novel biomarkers of IBD activity by mass spectrometric screening of urine and/or saliva samples.
IRAS ID
163203
Contact name
Daniel Gaya
Contact email
Clinicaltrials.gov Identifier
GN14GA455, Research and Development
Duration of Study in the UK
0 years, 6 months, 31 days
Research summary
The role of the microbes in maintaining the health of the gastrointestinal (GI)tract has become widely appreciated in recent years. Alterations in the population of microbes may contribute to diseases of the GI and produce diseases such as irritable bowel disease (IBD).The microbial population contribute many metabolites which are found in human physiological fluids and it may be possible to observe alterations in the microbe population by profiling metabolites in fluids such as urine or plasma. If it is possible to do this then key marker compounds might be discovered which could provide a means diagnosing disease and monitoring the success of its treatment.We thus propose a pilot study to ascertain whether these methods work in our IBD patients urine and saliva samples and to estimate the likely numbers of recruits needed for a larger study
REC name
London - Queen Square Research Ethics Committee
REC reference
14/LO/2304
Date of REC Opinion
5 Jan 2015
REC opinion
Further Information Favourable Opinion